A Review of Current and Evolving Imaging Techniques in Cardiac Amyloidosis

[1]  P. Collier,et al.  Racial and Genetic Differences in Presentation of Transthyretin Amyloid Cardiomyopathy With Impaired Left Ventricular Function. , 2022, JACC. Heart failure.

[2]  Joao A. C. Lima,et al.  Supranormal Left Ventricular Ejection Fraction, Stroke Volume, and Cardiovascular Risk: Findings From Population-Based Cohort Studies. , 2022, JACC. Heart failure.

[3]  P. Kellman,et al.  Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment , 2022, European heart journal.

[4]  O. Simonetti,et al.  T2 mapping in myocardial disease: a comprehensive review , 2022, Journal of Cardiovascular Magnetic Resonance.

[5]  P. Martens,et al.  Supra-normal left ventricular ejection fraction in cardiac amyloidosis , 2022, Clinical Research in Cardiology.

[6]  M. Fontana,et al.  Imaging-Guided Treatment for Cardiac Amyloidosis , 2022, Current Cardiology Reports.

[7]  J. Estep,et al.  The Association of Cardiac Biomarkers, the Intensity of Tc99 Pyrophosphate Uptake, and Survival in Patients Evaluated for Transthyretin Cardiac Amyloidosis in the Early Therapeutics Era. , 2022, Journal of cardiac failure.

[8]  M. Emdin,et al.  Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review. , 2022, Journal of the American College of Cardiology.

[9]  J. Bourque,et al.  Temporal Trends in Diagnostic Testing Patterns for Wild-Type Transthyretin Amyloid Cardiomyopathy in the Medicare Fee-for-Service Population. , 2022, The American journal of cardiology.

[10]  Yuchi Han,et al.  Electrocardiogram Characteristics and Prognostic Value in Light-Chain Amyloidosis: A Comparison With Cardiac Magnetic Resonance Imaging , 2021, Frontiers in Cardiovascular Medicine.

[11]  M. Maurer,et al.  ATTR Amyloidosis: Current and Emerging Management Strategies , 2021, JACC. CardioOncology.

[12]  M. Bietenbeck,et al.  CMR-based T1-mapping offers superior diagnostic value compared to longitudinal strain-based assessment of relative apical sparing in cardiac amyloidosis , 2021, Scientific Reports.

[13]  M. Beksac,et al.  Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. , 2021, The New England journal of medicine.

[14]  C. Hengstenberg,et al.  Machine learning-derived electrocardiographic algorithm for the detection of cardiac amyloidosis , 2021, Heart.

[15]  M. Maurer,et al.  Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis. , 2021, Circulation research.

[16]  Peter R. Huntjens,et al.  Prognostic Utility of Echocardiographic Atrial and Ventricular Strain Imaging in Patients With Cardiac Amyloidosis. , 2021, JACC. Cardiovascular imaging.

[17]  W. Tang.  Faculty Opinions recommendation of Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. , 2021, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[18]  A. Petrie,et al.  Abstract 13148: Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis , 2020, Circulation.

[19]  Rahul C. Deo,et al.  Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms , 2020, Nature Communications.

[20]  P. Kellman,et al.  Reduction in CMR Derived Extracellular Volume with Patisiran Indicates Cardiac Amyloid Regression. , 2020, JACC. Cardiovascular imaging.

[21]  A. Vacca,et al.  Right Heart Changes Impact on Clinical Phenotype of Amyloid Cardiac Involvement: A Single Centre Study , 2020, Life.

[22]  M. Emdin,et al.  Electromechanical dissociation of left atrium in patients with Cardiac Amyloidosis by Magnetic Resonance: Prognostic and clinical correlates , 2020, International journal of cardiology. Heart & vasculature.

[23]  H. Nagaraja,et al.  Novel Cardiovascular Magnetic Resonance Model to Distinguish Immunoglobulin Light Chain From Transthyretin Cardiac Amyloidosis. , 2020, JACC. Cardiovascular imaging.

[24]  R. Doukky,et al.  Comparison of planar with tomographic pyrophosphate scintigraphy for transthyretin cardiac amyloidosis: Perils and pitfalls , 2020, Journal of Nuclear Cardiology.

[25]  E. Klotz,et al.  Identifying Cardiac Amyloid in Aortic Stenosis , 2020, JACC. Cardiovascular imaging.

[26]  R. Falk,et al.  Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis: JACC Review Topic of the Week. , 2020, Journal of the American College of Cardiology.

[27]  M. Salerno,et al.  Native T1 Mapping, Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis: A Meta-Analysis. , 2020, JACC. Cardiovascular imaging.

[28]  J. Grégoire,et al.  Tc-99m-pyrophosphate scintigraphy for the diagnosis of ATTR cardiac amyloidosis: Comparison of quantitative and semi-quantitative approaches , 2020, Journal of Nuclear Cardiology.

[29]  Randall C. Thompson,et al.  Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: Imaging at 1 vs 3 hours and planar vs SPECT/CT , 2020, Journal of Nuclear Cardiology.

[30]  D. Pennell,et al.  Diffusion Tensor Cardiovascular Magnetic Resonance in Cardiac Amyloidosis , 2020, Circulation. Cardiovascular imaging.

[31]  S. Shiraishi,et al.  Quantification of Myocardial Extracellular Volume With Planning Computed Tomography for Transcatheter Aortic Valve Replacement to Identify Occult Cardiac Amyloidosis in Patients With Severe Aortic Stenosis. , 2020, Circulation. Cardiovascular imaging.

[32]  M. Maurer,et al.  How Should Physicians Assess Myocardial Contraction?: Redefining Heart Failure With a Preserved Ejection Fraction. , 2020, JACC. Cardiovascular imaging.

[33]  James A. White,et al.  Determinants and Prognostic Significance of Serial Right Heart Function Changes in Patients With Cardiac Amyloidosis. , 2020, The Canadian journal of cardiology.

[34]  E. Braunwald,et al.  Atrial Failure as a Clinical Entity: JACC Review Topic of the Week. , 2020, Journal of the American College of Cardiology.

[35]  A. Petrie,et al.  Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. , 2020, European heart journal.

[36]  J. Moon,et al.  Identifying Cardiac Amyloid in Aortic Stenosis: ECV Quantification by CT in TAVR Patients , 2020 .

[37]  R. Falk,et al.  How to Image Cardiac Amyloidosis: A Practical Approach. , 2020, JACC. Cardiovascular imaging.

[38]  M. Benson,et al.  Inotersen therapy of transthyretin amyloid cardiomyopathy , 2019, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[39]  M. Salerno,et al.  Myocardial T1 and ECV Measurement: Underlying Concepts and Technical Considerations. , 2019, JACC. Cardiovascular imaging.

[40]  M. Liedtke,et al.  AL Amyloidosis for the Cardiologist and Oncologist , 2019, JACC. CardioOncology.

[41]  C. Rapezzi,et al.  Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. , 2019, Circulation. Heart failure.

[42]  Sanjiv J. Shah,et al.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging , 2019, Journal of Nuclear Cardiology.

[43]  M. Maurer,et al.  Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.

[44]  F. Dominici,et al.  Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. , 2019, Circulation. Heart failure.

[45]  Kihyun Kim,et al.  Associations of Electrocardiographic Parameters with Left Ventricular Longitudinal Strain and Prognosis in Cardiac Light Chain Amyloidosis , 2019, Scientific Reports.

[46]  J. Moon,et al.  Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles. , 2019, JACC. Cardiovascular imaging.

[47]  P. Kellman,et al.  Native T1 and Extracellular Volume in Transthyretin Amyloidosis. , 2019, JACC. Cardiovascular imaging.

[48]  J. Moon,et al.  High Prevalence of Intracardiac Thrombi in Cardiac Amyloidosis. , 2019, Journal of the American College of Cardiology.

[49]  M. Kürtüncü,et al.  Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis , 2019, Turkish Journal Of Neurology.

[50]  J. D’hooge,et al.  Velocities of Naturally Occurring Myocardial Shear Waves Increase With Age and in Cardiac Amyloidosis. , 2019, JACC. Cardiovascular imaging.

[51]  Roger D. White,et al.  Direct Current Cardioversion of Atrial Arrhythmias in Adults With Cardiac Amyloidosis. , 2019, Journal of the American College of Cardiology.

[52]  O. Suhr.  Commentary to Isabel Conceição et al. early diagnosis through targeted follow-up of identified carriers of TTR gene mutations , 2019, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[53]  I. Conceição,et al.  Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations* , 2019, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[54]  C. Izumi,et al.  Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy , 2018, ESC heart failure.

[55]  R. Falk,et al.  State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis , 2018, Journal of Nuclear Cardiology.

[56]  Sanjiv J. Shah,et al.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.

[57]  S. Solomon,et al.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[58]  M. Sheppard,et al.  Myocardial Edema and Prognosis in Amyloidosis. , 2018, Journal of the American College of Cardiology.

[59]  P. Milani,et al.  Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis , 2018, Circulation. Cardiovascular imaging.

[60]  J. Moon,et al.  Prevalence of Cardiac Amyloidosis in Patients Referred for Transcatheter Aortic Valve Replacement , 2018, Journal of the American College of Cardiology.

[61]  M. Maurer,et al.  Myocardial Contraction Fraction: A Volumetric Measure of Myocardial Shortening Analogous to Strain. , 2018, Journal of the American College of Cardiology.

[62]  Jian Li,et al.  The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis , 2018, Journal of Cardiovascular Magnetic Resonance.

[63]  V. Aboyans,et al.  Left atrial function in patients with light chain amyloidosis: A transthoracic 3D speckle tracking imaging study. , 2017, Journal of cardiology.

[64]  M. Cerqueira,et al.  Regional Variation in Technetium Pyrophosphate Uptake in Transthyretin Cardiac Amyloidosis and Impact on Mortality. , 2017, JACC. Cardiovascular imaging.

[65]  Jennifer E Liu,et al.  Prognostic and Added Value of Two‐Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation , 2018, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[66]  P. Kellman,et al.  CMR-Verified Regression of Cardiac AL Amyloid After Chemotherapy. , 2018, JACC. Cardiovascular imaging.

[67]  D. Forman,et al.  Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis , 2017, Journal of Cardiovascular Magnetic Resonance.

[68]  C. Izumi,et al.  Predictors of Prognosis in Light-Chain Amyloidosis and Chronological Changes in Cardiac Morphology and Function. , 2017, The American journal of cardiology.

[69]  M. Hanna,et al.  Cardiac amyloidosis: An update on diagnosis and treatment , 2017, Cleveland Clinic Journal of Medicine.

[70]  M. Wheeler,et al.  Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry). , 2017, The American journal of cardiology.

[71]  M. Leon,et al.  Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement , 2017, European heart journal.

[72]  S. Solomon,et al.  Left atrial structure and function in cardiac amyloidosis , 2017, European heart journal cardiovascular Imaging.

[73]  Stefan K. Piechnik,et al.  Measurement of myocardial native T1 in cardiovascular diseases and norm in 1291 subjects , 2017, Journal of Cardiovascular Magnetic Resonance.

[74]  H. Feigenbaum,et al.  Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy , 2017, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[75]  D. Seldin,et al.  Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis , 2017, European heart journal cardiovascular Imaging.

[76]  Yuchi Han,et al.  Right ventricular involvement evaluated by cardiac magnetic resonance imaging predicts mortality in patients with light chain amyloidosis , 2017, Heart and Vessels.

[77]  P. Elliott,et al.  Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis , 2017, Circulation.

[78]  Q. Fang,et al.  Clinical correlates and prognostic values of pseudoinfarction in cardiac light-chain amyloidosis. , 2016, Journal of cardiology.

[79]  J. Goldsmith,et al.  Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis. , 2016, JAMA cardiology.

[80]  W. Mazur,et al.  Clinical and prognostic utility of cardiovascular magnetic resonance imaging in myeloma patients with suspected cardiac amyloidosis. , 2016, European heart journal cardiovascular Imaging.

[81]  J. Stone,et al.  Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis. , 2016, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[82]  S. K. White,et al.  Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement. , 2016, Circulation. Cardiovascular imaging.

[83]  R. Hachamovitch,et al.  Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. , 2016, International journal of cardiology.

[84]  J. Deux,et al.  Prognostic value of right ventricular systolic function in cardiac amyloidosis , 2016, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[85]  C. Rapezzi,et al.  Coexistence of Degenerative Aortic Stenosis and Wild-Type Transthyretin-Related Cardiac Amyloidosis. , 2016, JACC. Cardiovascular imaging.

[86]  D. Phelan,et al.  Prognostic implication of relative regional strain ratio in cardiac amyloidosis , 2016, Heart.

[87]  B. Bettencourt,et al.  Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis , 2016, Journal of Nuclear Cardiology.

[88]  P. Kellman,et al.  Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis , 2015, Circulation.

[89]  R. Falk,et al.  18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study , 2015, Circulation. Cardiovascular imaging.

[90]  M. Maurer,et al.  The myocardial contraction fraction is superior to ejection fraction in predicting survival in patients with AL cardiac amyloidosis , 2015, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[91]  B. Bijnens,et al.  Predictive Value of Assessing Diastolic Strain Rate on Survival in Cardiac Amyloidosis Patients with Preserved Ejection Fraction , 2014, PloS one.

[92]  J. Goldsmith,et al.  Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. , 2014, The American journal of cardiology.

[93]  L. Anderson,et al.  CMR-based differentiation of AL and ATTR cardiac amyloidosis. , 2014, JACC. Cardiovascular imaging.

[94]  M. Robson,et al.  T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. , 2013, JACC. Cardiovascular imaging.

[95]  James D. Thomas,et al.  Incremental prognostic value of assessing left ventricular myocardial mechanics in patients with chronic systolic heart failure. , 2012, Journal of the American College of Cardiology.

[96]  P. Pellikka,et al.  Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratification in primary systematic (AL) amyloidosis: a 5-year cohort study. , 2012, European heart journal cardiovascular Imaging.

[97]  James D. Thomas,et al.  Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis , 2012, Heart.

[98]  L. Padeletti,et al.  Right ventricular function in AL amyloidosis: characteristics and prognostic implication. , 2012, European heart journal cardiovascular Imaging.

[99]  P. Pibarot,et al.  Left atrial size is an independent predictor of overall survival in patients with primary systemic amyloidosis. , 2011, Archives of cardiovascular diseases.

[100]  F. Salvi,et al.  Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. , 2011, JACC. Cardiovascular imaging.

[101]  R. Falk,et al.  Prognostic significance of strain Doppler imaging in light-chain amyloidosis. , 2010, JACC. Cardiovascular imaging.

[102]  Matthew W. Martinez,et al.  Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. , 2010, JACC. Cardiovascular imaging.

[103]  D. Pennell,et al.  Journal of Cardiovascular Magnetic Resonance Open Access Cardiovascular Magnetic Resonance and Prognosis in Cardiac Amyloidosis , 2022 .

[104]  B. Hazenberg,et al.  Diagnostic Performance and Prognostic Value of Extravascular Retention of 123I-Labeled Serum Amyloid P Component in Systemic Amyloidosis , 2007, Journal of Nuclear Medicine.

[105]  R. Falk,et al.  Prognostic Significance of Ultrasound Myocardial Tissue Characterization in Patients With Cardiac Amyloidosis , 2002, Circulation.

[106]  D. King,et al.  Myocardial contraction fraction: a volumetric index of myocardial shortening by freehand three-dimensional echocardiography. , 2002, Journal of the American College of Cardiology.

[107]  M. Pepys,et al.  Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. , 1990, The New England journal of medicine.